2023 ARRS ANNUAL MEETING - ABSTRACTS

RETURN TO ABSTRACT LISTING


E2673. Efficacy of Empirical Transarterial Embolization in the Cancer-Related Chronic Gastrointestinal Bleeding
Authors
  1. Byung Chan Lee; Chonnam National University Hospital
  2. Hyoung Ook Kim; Chonnam National University Hospital
  3. Byung Hyun Baek; Chonnam National University Hospital
Objective:
To evaluate the efficacy of empirical transarterial embolization (TAE) for cancer-related uncontrolled chronic gastrointestinal bleeding without active bleeding on computed tomography (CT).

Materials and Methods:
Among patients with advanced cancer-related gastrointestinal bleeding for which endoscopic hemostasis was not possible, 26 patients (M: F = 17:9, mean age: 67.5) who underwent TAE were included in this retrospective study. Patients were divided into two groups with active bleeding (group 1) and without active bleeding (group 2) on CT before TAE. Patients’ clinical characteristics, imaging features, and clinical outcomes were investigated. Clinical success was defined as the disappearance of bleeding symptoms within 24 hours and no rebleeding for 30 days. Comparative analysis between two groups was performed using the Chi-square and Fisher's exact test for categorical data and the Mann-Whitney test for continuous data.

Results:
Group1 included 14 patients (M: F = 8:6, mean age: 66.4) and the group2 included 12 patients (M: F = 9:3, mean age: 68.6). The baseline and tumor characteristics of the patients before the procedure were statistically not different between the two groups (p > 0.05). Clinical success rates of TAE for group1 and group2 were 78.5% and 83.3% (p = 0.759). Post-TAE shock index score decreased by 0.4 ±0.4 in group1 and 0.2 ±0.3 in group2, and there was no statistical difference (p = 0.076). The rebleeding rates were higher in group 1 than group2 (21.4% vs 8.3%), but there was no statistical difference (p = 0.306).

Conclusion:
Even if CT does not show active bleeding in patients with cancer-related chronic GI bleeding, empiric TAE might help bleeding control.